Menu
Search
|

Menu

Close
X

Paratek Pharmaceuticals Inc PRTK.OQ (NASDAQ Stock Exchange Global Market)

5.76 USD
+0.16 (+2.86%)
As of Sep 13
Previous Close 5.60
Open 5.55
Volume 169,992
3m Avg Volume 108,430
Today’s High 5.89
Today’s Low 5.42
52 Week High 12.18
52 Week Low 2.88
Shares Outstanding (mil) 32.42
Market Capitalization (mil) 106.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
2
FY18
17
FY17
13
FY16
0
EPS (USD)
FY19
-1.101
FY18
-3.569
FY17
-3.359
FY16
-5.670
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
5.70
7.90
Price to Book (MRQ)
vs sector
6.65
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
1,429.99
17.64
LT Debt to Equity (MRQ)
vs sector
1,429.99
12.61
Return on Investment (TTM)
vs sector
-57.06
12.69
Return on Equity (TTM)
vs sector
-189.62
17.13

EXECUTIVE LEADERSHIP

Michael Bigham
Executive Chairman of the Board, Since 2019
Salary: $500,000.00
Bonus: --
Adam Woodrow
President and Chief Commercial Officer, Since 2019
Salary: $348,200.00
Bonus: $28,030.00
Evan Loh
Chief Executive Officer, Chief Operating Officer, Principal Executive Officer, Director, Since 2019
Salary: $480,000.00
Bonus: --
Sarah Higgins
Interim Principal Financial Officer and Principal Accounting Officer, Since 2019
Salary: --
Bonus: --
William Haskel
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary, Since 2015
Salary: $348,200.00
Bonus: $28,030.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75 Park Plz Ste 4
BOSTON   MA   02116-3934

Phone: +1617.8076600

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

SPONSORED STORIES